MoonLake ImmunotherapeuticsMLTX
About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Employees: 100
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
55% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 31
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
32% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $8.56M
9% more capital invested
Capital invested by funds: $3.14B [Q3] → $3.43B (+$294M) [Q4]
6% more funds holding
Funds holding: 109 [Q3] → 115 (+6) [Q4]
1.55% more ownership
Funds ownership: 99.02% [Q3] → 100.57% (+1.55%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Serge Belanger 50% 1-year accuracy 62 / 125 met price target | 57%upside $66 | Buy Reiterated | 30 Apr 2025 |
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 69 met price target | 59%upside $67 | Outperform Initiated | 18 Mar 2025 |
Goldman Sachs Richard Law 63% 1-year accuracy 5 / 8 met price target | 73%upside $73 | Buy Maintained | 27 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 328 met price target | 138%upside $100 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 3 articles about MLTX published over the past 30 days








